Sanofi (Euronext: SAN) shares were up by nearly 4% during Thursday’s early afternoon trading in Paris following its results presentation.
The French pharma major had earlier presented its first-quarter 2024 financial results, revealing a 2% rise in sales to 10.46 billion euros ($11.22 billion), and business operating income for the period at 2.84 billion euros, a 15% decline compared to the same period a year ago.
Both figures beat a consensus of analyst predictions by more than 2%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze